During the infusion process, rituximab has been linked to hypotension, hypoxia, acute myocardial infarction, arrhythmias, and cardiogenic shock. There have also been reports of rituximab causing non-ischemic dilated cardiomyopathy. Patients who are treated with rituximab should be monitored for changes in their heart rate, blood pressure, and oxygen levels.
Non-ischaemic dilated cardiomyopathy is a condition where the heart muscle becomes damaged over time without having first received an injury from another cause such as smoking, alcohol abuse, viral infections, etc. As the muscle weakens, it becomes less able to pump blood efficiently, which can lead to heart failure. There is no cure for this condition at present, but patients often make a full recovery if diagnosed and treated early.
Cardiac side effects have been reported during cancer treatment too. Cancer drugs can damage the heart muscles or interfere with normal heart rhythms. This can happen regardless of how much radiation you receive or what type of chemotherapy you go through. Cardiotoxic drugs include doxorubicine, epirubicin, mitoxantrone, trastuzumab, and valrubicin. These drugs can cause heart problems including congestive heart failure, abnormal heart rhythms, and cardiac arrest. Some people may be more susceptible to these drug-induced injuries than others.
Furthermore, Rituximab may promote immunosuppression through a variety of mechanisms, including delayed-onset cytopenia, notably neutropenia and hypogammaglobulinemia. Clinical research have yielded contradictory outcomes in terms of rituximab's connection with infections. Some studies have reported increased rates of infection while others have not found evidence of this effect.
There is some evidence that rituximab may increase your risk of contracting hepatitis B or C. Patients who receive the drug should be vaccinated against tetanus, diphtheria, pertussis (whooping cough), measles, mumps, and rubella.
The use of rituximab is associated with adverse effects. Common side effects include nausea, diarrhea, fatigue, fever, chills, headache, vomiting, abdominal pain, cough, sore throat, runny nose, mouth sores, changes in the color of urine, or symptoms of hormone imbalance. In rare cases, patients have experienced heart problems or allergic reactions after receiving rituximab.
Rituximab is used to treat certain types of cancer. It works by destroying B cells that play a role in immune response. By removing these cells, patients are less likely to develop resistance to cancer cells.
Following a review of the literature, the CDC and NIOSH recommendations determined that Rituximab is not a dangerous medicine and has no adverse health consequences when it comes into contact with the eyes, skin, or mucous membranes (Genentech, 2011).
However, because this drug can cause serious side effects, it is important to know how to use it safely. The National Institute for Occupational Safety and Health (NIOSH) reviewed available data on occupational exposures to Rituximab and concluded that it is not likely to be harmful if proper protective measures are taken.
Rituximab is the name of the medication product used to treat certain types of cancer. It works by destroying B cells, which play an important role in immune response. By removing B cells, the body's defense mechanism is weakened and patients become more vulnerable to infection.
Healthy tissues usually protect themselves from toxic substances in the environment by clearing them out of the body quickly. However, because B cells are found in many different parts of the body, including the bone marrow, lungs, and brain, killing them using Rituximab could have severe side effects. Patients who take this drug should be closely monitored by their doctors during treatment and for some time after they stop taking it.
In a clinical trial with 222 lymphoma patients, nine of them had ocular adverse effects such as conjunctivitis, transitory ocular edema, a burning sensation, and a transient or permanent, even severe, loss of visual function. > span
These problems were caused by the monoclonal antibody Rituximab. It is used to treat cancer, but it can also cause serious side effects. In this article we will explain what role Rituximab plays in the treatment of cancer and why it may be difficult for some people to stop taking it.
Cancer Treatment: Rituximab blocks proteins called CD20 that are found on certain types of white blood cells (B-cells) and on certain cancer cells. By blocking these proteins, Rituximab prevents B-cells from producing antibodies against other substances (antigens) that would normally tell their body's immune system to attack foreign objects such as cancer cells. This means that Rituximab can prevent your body from creating its own defenses against cancer. As a result, Rituximab can help destroy tumors by causing the patient's immune system to fight off cancer cells.
Rituximab is used in combination with other treatments for non-Hodgkin's lymphomas.
Rituximab therapeutic levels may be maintained in dialysis patients. Hemodialysis does not remove rituximab. Peritoneal dialysis and hemodiafiltration remove some proteins from the blood, but not enough to affect drug levels.
Dialysis treatment removes waste products and excess water from the body through the kidneys or other organs such as the heart. Waste products include urea nitrogen (BUN) and creatinine. The amount of time that you can live without your kidney function decreasing too much is called the "survival time" for people with chronic kidney disease (CKD). Most patients who need renal replacement therapy (dialysis or transplantation) die before they reach end-stage renal disease (ESRD). However, about one third of patients survive longer than 10 years after starting dialysis treatment.
About half of all people with CKD will require some form of renal replacement therapy by the time they reach ESRD. Factors leading to the need for dialysis or transplantation include high levels of BUN and creatinine, which result from poor nutrition and excessive removal of nutrients and minerals during dialysis treatments; increasing acidity due to poor clearance of urine; decreased ability to fight infection; and loss of muscle mass caused by lack of proper nutrition.
Rituximab is used to treat certain types of cancer (e.g., non-lymphoma, Hodgkin's chronic lymphocytic leukemia) either alone or in combination with other medications. A monoclonal antibody is a type of medicine. It works by binding to specific proteins on the surface of some cells and triggering an immune response. This may help kill such cells that have grown into tumors.
Rituximab is made from rabbits injected with human blood cells. The resulting serum is then mixed with alcohol to remove any contaminants before being frozen in aliquots for future use.
The medication is administered as a shot into a large muscle, such as the thigh. It must be taken very carefully not to spill any of the liquid substance. Doing so could cause serious harm due to the risk of infection.
It takes about two weeks for all of the antibodies in rituximab to work their way through your body. During this time, you should avoid exposure to sunlight because the ultraviolet rays can damage the photosensitive chemicals contained within the package insert. Also, women who are pregnant or may become pregnant should not take rituximab.